Edition:
United States

Zoetis Inc (ZTS.N)

ZTS.N on New York Stock Exchange

62.58USD
25 May 2017
Change (% chg)

-- (--)
Prev Close
$62.58
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
909,562
52-wk High
$62.63
52-wk Low
$45.28

ZTS.N

Chart for ZTS.N

About

Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock)... (more)

Overall

Beta: 1.04
Market Cap(Mil.): $30,714.07
Shares Outstanding(Mil.): 490.80
Dividend: 0.10
Yield (%): 0.67

Financials

  ZTS.N Industry Sector
P/E (TTM): 36.39 14.31 17.43
EPS (TTM): 1.72 -- --
ROI: 14.04 -7.26 -5.41
ROE: 61.64 -6.76 -4.69

BRIEF-Zoetis gets grant from Bill & Melinda Gates foundation to develop sustainable livestock production in sub-Saharan Africa

* Will receive $14.4 million grant from Bill & Melinda Gates foundation over next 3 years

May 08 2017

BRIEF-Zoetis Q1 adjusted earnings per share $0.53

* Q1 earnings per share view $0.48 -- Thomson Reuters I/B/E/S

May 04 2017

BRIEF-Zoetis gets European Commission marketing authorization for Cytopoint

* Zoetis receives european commission marketing authorization for Cytopoint® (lokivetmab) Source text for Eikon: Further company coverage:

Apr 26 2017

BRIEF-Zoetis to acquire Nexvet for US$6.72 in Cash Per Share

* Zoetis to acquire Nexvet Biopharma, an innovator in monoclonal antibody therapies for companion animals

Apr 13 2017

BRIEF-Zoetis CEO's 2016 total compensation was $9.5 million

* CEO Juan Ramón Alaix's 2016 total compensation was $9.5 million versus $8.7 million in 2015 Source text:(http://bit.ly/2nRVXcH) Further company coverage:

Mar 31 2017

BRIEF-Zoetis reports Q4 EPS $0.31

* Q4 earnings per share view $0.45 -- Thomson Reuters I/B/E/S

Feb 16 2017

BRIEF-Zoetis receives European commission approval for stronghold plus

* Zoetis receives European commission approval for stronghold plus Source text for Eikon: Further company coverage:

Feb 15 2017

BRIEF-Pershing Square dissolves sole share stake in Zoetis Inc

* Pershing Square Capital Management dissolves sole share stake in Zoetis Inc - SEC filing

Feb 14 2017

More From Around the Web

Competitors

  Price Chg
Merck & Co., Inc. (MRK.N) $65.04 --
Bayer AG (BAYGn.DE) €116.70 -0.05
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €87.10 -0.21
Eli Lilly and Co (LLY.N) $78.34 --

Earnings vs. Estimates